Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F039 - Where Do We Stand? The Pathogenesis and Treatment of Melasma

Friday, February 16; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Succinctly review new data on the diagnosis and pathogenesis of melasma.
  • Discuss treatment options including hydroquinone, and non-hydroquinone lightening agents, as well as new targets and emerging technologies.
  • Review resurfacing technologies including the benefits and risks associated with each procedure.

Description

Melasma is indeed a global disorder of major cosmetic significance. It negatively impacts the quality of life of patients. The pathogenesis of melasma is indeed complex. Multiple recent studies document the interplay of genetics, inflammation, oxidative stress, abnormal vascular responses, and sensitivity to hormones in the pathogenesis of this disorder. While there are no cures, multiple new therapies offer significant improvement. This forum will review the most recent global advances in the pathogenesis and treatment of melasma. Therapies to be reviewed include sunscreens, topical agents, and oral agents including tranexamic acid, chemical peels, micro needling, lasers, and light sources. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Arellano-Mendoza, Maria Ivonne, MD: Bioderma – SP(H); Galderma Laboratories, LP – A(H); Pierre Fabre Dermo Cosmetique France – A(H); Sanfer, S.L. – SP(H);
  • Desai, Seemal R., MD: AbbVie – C(Fees), I(Grants/Research Funding), SP(H); Allergan, Inc – C(Fees); Anacor Pharmaceuticals, Inc. – C(Fees); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(Fees); Foamix – I(Grants/Research Funding); Galderma Laboratories, LP – C(Fees), SP(H); Innovaderm Research Inc. – I(Grants/Research Funding); Menlo Therapeutics – C(H), I(Grants/Research Funding); Novan – I(Grants/Research Funding); Par Pharmaceutical – I(Grants/Research Funding); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Symbio – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(Fees), SP(H);
  • Grimes, Pearl E., MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Clinuvel – I(H); Derm Tech International – I(H); Galderma Laboratories, L.P. – C(Grants/Research Funding), C(H); Incyte Corporation – I(Grants/Research Funding); Kythera – I(H); Laseroptek USA – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Obagi Medical Products – I(H); Procter & Gamble Company – C(H); Suneva Medical, Inc. – I(H); VT Technologies – I(Grants/Research Funding);
  • Narurkar, Vic A., MD: Allergan, Inc. – A(Grants/Research Funding), I(Fees); Medicis Pharmaceutical Corporation – C(H); Merz Aesthetics – C(H); MyoScience – I(SO); Palomar Medical Technologies – I(Grants/Research Funding); Revance Therapeutics, Inc. – A(SO); Solta Medical – I(Grants/Research Funding);
  • Rendon, Marta I., MD: A(H), Speaker/Faculty Education(H); Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Galderma Research & Development, LLC – I(Grants/Research Funding); Galderma USA – A(H), Speaker/Faculty Education(H); L'Oreal USA Inc. – A(H); Leo Pharma Inc – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Merz Aesthetics – A(H), Speaker/Faculty Education(H); Pierre Fabre Dermo-Cosmétique US – C(H); Sensus Healthcare – A(NC); Valeant Pharmaceuticals International – A(H);
  • Wambier, Carlos, MD: Cynosure – Speaker/Faculty Education(Fees); Galderma Brasil Ltda – SP(Fees);
Schedule
Friday, February 16
3:30 PM
Dr. Grimes / Introduction
3:35 PM
Dr. Grimes / Pathogenesis of Melasma
3:50 PM
Dr. Arellano-Mendoza / Topical and Oral Photoprotection
4:07 PM
Dr. Rendon / Microneedling and Other Emerging Technologies
4:24 PM
Dr. Wambier / Chemical Peels
4:41 PM
Dr. Narurkar / Lasers/Light Sources
4:58 PM
Dr. Desai / Topical Lightening Agents
5:15 PM
All faculty / Q&A
Event Details
  • Date
    Friday, February 16
  • Time
    3:30 PM - 5:30 PM
  • Location
    Ballroom 20B
  • CME Credits
    2.00
  • Type
    MOC
Directors/Co-Directors
  • Pearl E. Grimes, MD, FAAD
Speakers
  • Carlos Wambier, MD - Handout
  • Maria Ivonne Arellano-Mendoza, MD - Handout
  • Marta I. Rendon, MD, FAAD
  • Seemal R. Desai, MD, FAAD - Handout
  • Vic A. Narurkar, MD, FAAD